The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 567-576

  Wang, Chao ^a   Thor, Ann D ^d   Moore II, Dan H ^e   Zhao, Yong ^a   Kerschmann, Russell ^c   Stern, Robert ^c   Watson, Peter H ^b   Turley, Eva A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIGENS, CD44; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYALURONIC ACID; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RAS PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 0031948476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Fisher, B., Osborne, C. K., Margolese, R. G., and Bloomer, W. D. Neoplasms of the breast. In: J. W. J. Pine (ed.), Cancer Medicine, pp. 2349-2429. Baltimore: Williams & Wilkins. 1997.
2. Weber, B. L., Couch, F. J., and Farid, L. M. Genetic analysis of susceptibility to inherited breast cancer with emphasis on BRCA1 and BRCA2. Adv. Pathol, 9: 361-391, 1996.
3. Stratton, M. R. Recent advances in understanding of genetic susceptibility of breast cancer. Hum. Mol. Genet, 5: 1515-1519, 1996.
4. Leong, A. S. Y., and Lee, A. K. C. Biological indices in the assessment of breast cancer. J. Clin. Pathol. Mol. Pathol., 48: M221-M238, 1995.
5. Walker, R. A., Jones, J. L., Chappell, C., Walsh, T., and Shaw, J. A. Molecular pathology of breast cancer and application to clinical management. Breast Cancer Res. Treat., 16: 5-27, 1997.
6. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
7. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
8. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 99: 1478-1483, 1997.
9. Hall, C. L., Yang, B., Yang, X., Zhang, S., Turley, M., Samuel, S., Lange, L. A., Wang, C., Curpen, G. D., Savani, R. C., Greenberg, A. H., and Turley, E. A. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell, 82: 19-26, 1995.
10. Aβmann, V., Kern, H. F., and Elsasser, H. P. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin. Cancer Res., 2: 1607-1618, 1996.
11. Teder, P., Bergh, J., and Heldin, P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res., 55: 3908-3914, 1995.
12. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
13. Hardwick, C., Hoare, K., Owens, R., Hohn, H. P., Hook, M., Moore, D., Cripps, V., Austen, L., Nance, D. M., and Turley, E. A. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J. Cell Biol., 117: 1343-1350, 1992.
14. Wang, C., Entwistle, J., Hou, G., Li, Q., and Turley, E. A. The characterization of a human RHAMM cDNA: conservation of the hyaluronan binding domains. Gene (Amst.), 174: 299-306, 1996.
15. Hiller, T., Snell, L. S., and Watson, P. H. Microdissection/RT-PCR analysis of gene expression in frozen tissue sections. Biotechniques, 21: 38-44, 1996.
16. Entwistle, J., Zhang, S., Yang, B., Wong, C., Li, Q., Hall, C. L., A, J., Mowat, M., Greenberg, A. H., and Turley, E. A. Characterization of the murine gene encoding the hyaluronan receptor RHAMM. Gene (Amst.), 163: 233-238, 1995.
17. Wang, C., Tammi, M., and Tammi, R. Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages. Histochemistry, 98: 105-112, 1992.
18. Savani, R. C., Wang, C., Yang, B., Zhang, S., Kinsella, M. G., Wight, T. N., Stern, R., Nance, D. M., and Turley, E. A. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. J. Clin. Invest, 95: 1158-1168, 1995.
19. Abacus Concepts. Survival Tools for StatView. Berkeley: Abacus Concepts Inc., 1994.
20. Lee, E. T. Statistical Methods for Survival Data Analysis. New York: John Wiley & Sons, 1995.
21. Mohapatra, S., Yang, X., Wright, J. A., Turley, E. A., and Greenberg, A. H. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J. Exp. Med., 183: 1663-1668, 1996.
22. Thor, A., Ohuchi, N., Horan Hand, P., Callahan, R., Weeks, M. O., Theillet, C., Lidereau, R., Escot, C., Page, D. L., Vilasi, V., and Schlom, J. Ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. Lab. Invest., 55: 603-615, 1986.
23. Leslie, K. O., and Howard, P. Oncogenes and antioncogenes in human breast carcinoma. Pathol. Annu., 27: 321-342, 1992.
24. Watson, D. M. A., Elton, R. A., Jack, W. J. L., Dixon, J. M., Chetty, U., and Miller, W. R. The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res. Treat., 17: 161-169, 1990.
25. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-170, 1996.
26. Schichman, S. A., and Croce, C. H. Oncogenes. In: J. W. J. Pine (ed.), Cancer Medicine, pp. 85-94, Baltimore: Williams & Wilkins, 1997.
27. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem., 270: 16483-16486, 1995.
28. Seger, R., and Krebs, E. G. The MAPK signaling cascade. FASEB J., 9: 726-735, 1995.
29. Klemke, R. L., Cai, S., Giannini, A. L., Gallagher, P. J., de Lanerolle, P., and Cheresh, D. A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell. Biol., 137: 481-492, 1997.
30. Reszka, A. A., Bulinski, C., Krebs, E. G., and Fischer, E. H. Mitogen-activated protein kinase/extracellular signaling-regulated kinase 2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions. Mol. Biol. Cell, 8: 1219-1232, 1997.
31. Levine, M. D., Liotta, L. A., and Stracke, M. L. Stimulation and regulation of tumor cell motility in invasion and metastasis. EXS, 74: 157-179, 1995.
32. Kantor, J. D., and Zetter, B. R. Cell motility in breast cancer. Cancer Treat. Res., 83: 303-323, 1996.
33. Hall, C. L., Wang, C., Lange, L. A., and Turley, E. A. Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol., 126: 575-588, 1994.
34. Irigoyen, J. P., Besser, D., and Nagamine, Y. Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the ras/extracellular signal-regulated kinase (ERK) signaling pathway. J. Biol. Chem., 272: 1904-1909, 1997.
35. Lengyel, E., Wang, H., Gum, R., Simon, C., Wang, Y., and Boyd, D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene, 14: 2563-2573, 1997.
36. Turley, E. A., Belch, A. J., Poppema, S., and Pilarski, L. M. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood, 81: 446-453, 1993.
37. Pilarski, L. M., Masellis-Smith, A., Belch, A. R., Yang, B., Savani, R. C., and Turley, E. A. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leuk. Lymph., 14: 363-374, 1994.
38. Masellis-Smith, A., Belch, A. R., Mant, M. J., Turley, E. A., and Pilarski, L. M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood, 87: 1891-1899, 1996.
39. Turley, E. A., Austen, L., Vandeligt, K., and Clary, C. Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. J. Cell Biol., 112: 1041-1047, 1991.
40. Turley, E. A., Austen, L., Moore, D., and Hoare, K. Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Exp. Cell Res., 207: 277-282, 1993.
41. c-src is required for cell locomotion regulated by the hyaluronan receptor RHAMM. Oncogene, 13: 2213-2224, 1996.
42. Turley, E. A. Hyaluronan and cell locomotion. Cancer Metastasis Rev., 11: 21-30, 1992.
43. Entwistle, J., Hall, C. L., and Turley, E. A. HA-receptors: regulators of signaling to the cytoskeleton. J. Cell. Biochem., 61: 569-577, 1996.
44. Hanks, S., and Polte, T. R. Signaling through focal adhesion kinase. BioEssays, 19: 137-145, 1997.
45. Thomas, L., Byers, H. R., Vink, J., and Stamenkovic, I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J. Cell Biol., 118: 971-977, 1992.
46. Sherman, L., Sleeman, J., Herrlich, P., and Ponta, H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell Biol., 6: 726-733, 1994.
47. Lesley, J., Hyman, R., and Kincade, P. W. CD44 and its interaction with extracellular matrix. Adv. Immunol., 54: 271-335, 1993.
48. Laurent, T. C., and Fraser, J. R. E. Hyaluronan. FASEB J., 6: 2397-2404, 1992.
49. Knudson, C. B., and Knudson, W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J., 7: 1233-1241, 1993.
50. Schuppan, D., Somasundaram, R., Dietrich, W., Ehnis, T., and Bauer, M. The extracellular matrix in cellular proliferation and differentiation. Ann. NY Acad. Sci., 733: 87-102, 1994.
51. Catterall, J. B., Gardner, M. J., and Turner, G. A. Hyaluronic acid, cell adhesion, and metastasis. Cancer J., 8: 320-324, 1995.
52. Wang, C., Tammi, M., Guo, H., and Tammi, R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am. J. Pathol., 148: 1861-1869, 1996.
53. Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., and Tanabe, K. K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene, 11: 2223-2232, 1995.
54. Gunthert, U., Stauder, R., Mayer, B., Terpe, H. J., Finke, L., and Friedrichs, K. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv., 24: 19-42, 1995.
55. Gunthert, U. CD44 in malignant disorders. Curr. Top. Microbiol. Immunol., 213(I): 271-285, 1996.
56. Naor, D., Sionov, R. V., and Ish-Shalom, D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 70: 241-319, 1997.
57. Rudzki, Z., and Jothy, S. CD44 and the adhesion of neoplastic cells. J. Clin. Pathol. Mol. Pathol., 50: 57-71, 1997.
58. Matsumura, Y., and Tarin, D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340: 1053-1058, 1992.
59. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G., Ponta, H., and Herrlich, P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345: 615-619, 1995.
60. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G., Ponta, H., and Herrlich, P. CD44 isoforms in prognosis of breast cancer. Lancet, 346: 502, 1995.
61. Guriec, N., Marcellin, L., Gairard, B., Calderoli, H., Wilk, A., Renaud, R., Bergerat, J. P., and Oberling, F. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin. Exp. Metastasis, 14: 434-439, 1996.
62. Regidor, P. A., Callies, R., Regidor, M., Gunthert, U., Zoller, M., and Schindler, A. E. Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch. Gynecol. Obstet., 258: 125-135, 1996.
63. Friedrichs, K., Franke, F., Lisboa, B. W., Kugler, G., Gille, I., Terpe, H. J., Holzel, F., Maass, H., and Gunthert, U. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res., 55: 5424-5433, 1995.
64. Friedrichs, K., Kugler, G., Franke, F., Terpe, H. J., Arlt, J., Regidor, P. A., and Gunthert, U. CD44 isoforms in prognosis of breast cancer. Lancet, 345: 1237, 1995.
65. Charpin, C., Garcia, S., Bouvier, C., Devictor, B., Andrac, L., Choux, R., Lavaut, M. N., and Allasia, C. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinoma. Hum. Pathol., 28: 289-296, 1997.